Personal Genome Diagnostics: Megan Bailey
Personal Genome Diagnostics has appointed Megan Bailey as its new CEO, succeeding Douglas Ward who served as the firm's CEO from 2016. Bailey initially joined PGDx as VP of marketing and was then promoted to chief commercial officer, leading the company’s marketing, sales, customer support, and communications arms in developing and executing global go-to-market strategies. She contributed to the achievement of CE marks for both the elio tissue complete assay and elio plasma resolve products and played a key role in establishing strategic collaborations with organizations such as the Mayo Clinic and PathGroup.
Before joining PGDx, Bailey spent more than 14 years at Roche, most recently as that firm's senior director of commercial operations. Prior to that, she held various marketing leadership roles for Roche's tissue diagnostics division.
HTG Molecular Diagnostics: Maureen Cronin
Maureen Cronin has resigned as CSO and senior VP at HTG Molecular Diagnostics, effective April 30. She will resume her consulting practice to pursue other interests, the company said. Cronin joined HTG Molecular in November 2018 after serving as executive director of strategic information management for Celgene from 2012 to 2017. Before that, she was senior VP of research and product development for Foundation Medicine. She also served as VP of translational research and senior director of technology development at Genomic Health.
Ancestry: Ronald Park
Ancestry has appointed Ronald Park as executive VP of health and DNA. In this role, Park will lead the company's AncestryHealth division. Park joins Ancestry after 16 years at Roche Pharmaceuticals, including international leadership roles at Roche and US roles at Genentech. Most recently, Park was co-leader of Roche Pharmaceuticals' personalized healthcare center of excellence. Park has also previously worked for Kaiser Permanente and McKinsey and Company's healthcare practice, and was a physician at the University of California, Los Angeles.
Mesa Biotech: Ingo Chakravarty
Mesa Biotech has appointed Ingo Chakravarty as the firm's president and CEO, effective April 15. Chakravarty replaces Hong Cai, a cofounder of Mesa, who has transitioned to be the firm's chief technology officer. Chakravarty most recently served as president and CEO of Navican Genomics and has held senior leadership positions at GenMark Diagnostics, Gen-Probe, Roche, and Ventana Medical Systems.
For additional recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.